ASKA sets 2035 long-term vision and unveils 2028 medium-term growth plan

The latest announcement is out from ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ).

ASKA Pharmaceutical Holdings has unveiled a long-term management blueprint dubbed ASKA VISION 2035, setting a 10-year ambition to achieve sustainable growth while enhancing its contribution to society through purpose-driven business execution. The strategy envisages reinforcing its established pharmaceutical franchise, especially in obstetrics and gynecology, while ramping up drug discovery, overseas expansion, and adjacent fields including animal health, diagnostics, and around-the-pill services.

As the first execution phase, the company launched its Medium-Term Management Plan 2028 starting in FY2026, targeting ¥85 billion in sales in FY2028 and laying the groundwork to reach ¥100 billion in revenue as soon as possible. The plan centers on five designated growth pillars supported by two foundational initiatives, aiming to balance steady expansion of existing businesses with building a robust platform for future growth and earnings stability.

The most recent analyst rating on (JP:4886) stock is a Buy with a Yen2624.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.

More about ASKA Pharmaceutical Holdings Co., Ltd.

ASKA Pharmaceutical Holdings Co., Ltd. is a Tokyo-based drugmaker listed on the TSE that has built its core business in pharmaceuticals, particularly in obstetrics and gynecology. The group is also cultivating related domains such as animal health, diagnostics, and around-the-pill solutions, with an eye on expanding its presence in overseas markets alongside its domestic operations.

Average Trading Volume: 142,014

Technical Sentiment Signal: Buy

Current Market Cap: Yen58.87B

For a thorough assessment of 4886 stock, go to TipRanks’ Stock Analysis page.